



RECEIVED

JAN 29 2004

TECH CENTER 1600/2900

PATENT
ATTORNEY DOCKET NO. 07180/004003

Certificate of Mailing: Date of Deposit: January 20, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Tracey Simmons
Printed name of person mailing correspondence

Tracey Simmons
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|---|---------------|--------------|
| Applicant: | Vassilis I. Zannis et al. | Art Unit: | 1636 |
| Serial No.: | 09/827,854 | Examiner: | Quang Nguyen |
| Filed: | April 5, 2001 | Customer No.: | 21559 |
| Title: | COMPOUNDS AND METHODS FOR LOWERING CHOLESTEROL LEVELS WITHOUT INDUCING HYPERTRIGLYCERIDEMIA | | |

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in


payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account
No. 03-2095.

Respectfully submitted,

Date:

Jan. 20, 2004



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 1

| | | | | | | |
|---|---|--|-----------------------------|-------------------------------------|----------|---------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | Attorney Docket No. 07180/004003 | | |
| | | | | Serial No. 09/827,854 | | |
| | | | | Applicant Vassilis I. Zannis et al. | | |
| | | | | Filing Date April 5, 2001 | | |
| | | | | Group 1636 | | |
| | | | | IDS Filed January 20, 2004 | | |
| | | | | Customer No. 21559 | | |
| U.S. PATENTS | | | | | | |
| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
| | | | | | | |
| | | | | | | |
| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | | | |
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
| | | | | | | |
| | | | | | | |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | | | | | | |
| | Chen et al., "Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low density lipoprotein receptor," <i>Molecular Therapy</i> 2:256-261 (2000). | | | | | |
| | Gerritsen et al., "Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain," <i>J. Lipid Research</i> 44:408-414 (2003). | | | | | |
| | Oka et al., "Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor," <i>Circulation</i> 103:1274-1281 (2001). | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| EXAMINER | | | DATE CONSIDERED | | | |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | | | | | | |